MNMD Stock Overview
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.91 |
| 52 Week High | US$12.22 |
| 52 Week Low | US$2.41 |
| Beta | 2.53 |
| 1 Month Change | -8.99% |
| 3 Month Change | 148.19% |
| 1 Year Change | 133.86% |
| 3 Year Change | -72.11% |
| 5 Year Change | n/a |
| Change since IPO | 2.31% |
Recent News & Updates
Recent updates
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20MindMed regains compliance with Nasdaq's minimum bid price listing requirement
Sep 14MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value
Sep 04Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Aug 26Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
Aug 24MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps
Aug 18Mind Medicine GAAP EPS of -$0.04 beats by $0.01
Aug 11Mind Medicine announces 1-for-15 reverse stock split
Aug 04MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount
Jul 12Mind Medicine: It's Best To Stay Far Away From This Risky Psychedelic Stock
Apr 20MindMed: Falling Uncontrollably
Jan 27Shareholder Returns
| MNMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.1% | -2.2% | -3.7% |
| 1Y | 133.9% | 11.6% | 20.5% |
Return vs Industry: MNMD exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: MNMD exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| MNMD volatility | |
|---|---|
| MNMD Average Weekly Movement | 19.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNMD's share price has been volatile over the past 3 months.
Volatility Over Time: MNMD's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Rob Barrow | www.mindmed.co |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MNMD fundamental statistics | |
|---|---|
| Market cap | US$628.16m |
| Earnings (TTM) | -US$95.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs MNMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$95.73m |
| Earnings | -US$95.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.1% |
How did MNMD perform over the long term?
See historical performance and comparison